CVR 44482096Private limited company (ApS)Fremstilling af farmaceutiske præparater (212000)SøborgFounded 28 Nov 2023
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about NEUROINNOVATECH ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
1
CVR, Jul 2026
Gross profit
-1M
DKK, annual report 2026
Result
-1.1M
DKK, annual report 2026
Equity
18.2M
DKK, annual report 2026
Alteral Therapeutics ApSCVR 43730967, 10% to under 15% of capital and votes
ABCHill Holding ApSCVR 43824015, 10% to under 15% of capital and votes
Operating company
Dandex estimate: 1 employee registered in 2026Christian Torben Hill-Madsensince 28 Jun 2024
Allan Traugott Wehnertsince 28 Jun 2024
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 4373096710% to under 15% of capital and votesnotified 31 Oct 2025since 28 Nov 2023
CVR 4382401510% to under 15% of capital and votesnotified 2 Jul 2024since 1 Jul 2024
CVR 387428095% to under 10% of capital and votesnotified 9 Dec 20251 Jul 2024 to 8 Dec 2025
CVR 3885197710% to under 15% of capital and votesnotified 31 Oct 202511 Jan 2024 to 31 Oct 2025
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Jul 2026, monthly: 1 employee, 1 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Jun 2026 | Jul 2026 |
|---|---|---|
| Employees | 1 | 1 |
| FTE | 1 | 1 |
| Series | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Jul 2026, published 22 Sep 2026.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2026, DKK: Gross profit -1M, Result for the year -1.1M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2026, DKK: Total assets 23.4M, Equity 18.2M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2025 | 2026 |
|---|---|---|
| Gross profit | -220 | -1,036 |
| Operating profit | Not reported | -1,053 |
| Result for the year | -237 | -1,059 |
| Equity | 923 | 18,221 |
| Total assets | 2,384 | 23,420 |
| Employees (average) | 0 | 1 |
| Credit metrics (Dandex calculations) | ||
| EBITDA | Not reportednote 1 | -1,036 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | |
| Employee growth (vækst i antal ansatte) | Not reportednote 2 | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | |
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | |
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | |
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | |
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | |
| Capex (investeringer i anlægsaktiver) | 1,228note 3 | 20,509note 3 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | |
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | |
Not every period is a full year: 2025 covers 17 months (28 Nov 2023 to 30 Apr 2025). Changes against it compare periods of different length.
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for NEUROINNOVATECH ApS:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 750,000, cash price 5,000.00, implied value 922,562,500 | 5,000.00 | 750,000 | 922,562,500 | 184,513 | |
| IncreaseCashPaid in 750,000, cash price 5,000.00, implied value 921,812,500 | 5,000.00 | 750,000 | 921,812,500 | 184,363 | |
| IncreaseCashPaid in 750,000, cash price 5,000.00, implied value 921,062,500 | 5,000.00 | 750,000 | 921,062,500 | 184,213 | |
| IncreaseCashPaid in 750,000, cash price 4,000.00, implied value 736,250,000 | 4,000.00 | 750,000 | 736,250,000 | 184,063 | |
| IncreaseCashPaid in 750,000, cash price 4,000.00, implied value 735,500,000 | 4,000.00 | 750,000 | 735,500,000 | 183,875 | |
| IncreaseCashPaid in 750,000, cash price 4,000.00, implied value 734,750,000 | 4,000.00 | 750,000 | 734,750,000 | 183,688 | |
| IncreaseCashPaid in 750,000, cash price 2,500.00, implied value 458,750,000 | 2,500.00 | 750,000 | 458,750,000 | 183,500 | |
| IncreaseCashPaid in 750,000, cash price 2,500.00, implied value 458,000,000 | 2,500.00 | 750,000 | 458,000,000 | 183,200 |
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 16,875,000, cash price 750.00, implied value 137,175,000 | 750.00 | 16,875,000 | 137,175,000 | 182,900 | |
| IncreaseCashPaid in 1,000,000, cash price 2,500.00, implied value 401,000,000 | 2,500.00 | 1,000,000 | 401,000,000 | 160,400 | |
| IncreaseCashPaid in 120,000 | None | 120,000 | None | 160,000 | |
| FoundingCashPaid in 40,000 | None | 40,000 | None | 40,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 18 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 18 Nov 2026.
21 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Vedtægter ændret: 10.11.2026
Kapitalforhøjelsen er besluttet den 10.11.2026.
kr. 150,00, indbetalt kontant, kurs 500.000,00.
Kapitalen udgør herefter kr. 184.512,50.
Vedtægter ændret: 15.07.2026
Kapitalforhøjelsen er besluttet den 15.07.2026.
kr. 150,00, indbetalt kontant, kurs 500.000,00.
Kapitalen udgør herefter kr. 184.362,50.
Vedtægter ændret: 16.06.2026
Kapitalforhøjelsen er besluttet den 16.06.2026.
kr. 150,00, indbetalt kontant, kurs 500.000,00.
Kapitalen udgør herefter kr. 184.212,50.
Vedtægter ændret: 13.05.2026
Kapitalforhøjelsen er besluttet den 13.05.2026.
kr. 187,50, indbetalt kontant, kurs 400.000,00.
Kapitalen udgør herefter kr. 184.062,50.
Vedtægter ændret: 30.04.2026
Kapitalforhøjelsen er besluttet den 30.04.2026.
kr. 187,50, indbetalt kontant, kurs 400.000,00.
Kapitalen udgør herefter kr. 183.875,00.
Vedtægter ændret: 04.03.2026
Kapitalforhøjelsen er besluttet den 04.03.2026.
kr. 187,50, indbetalt kontant, kurs 400.000,00.
Kapitalen udgør herefter kr. 183.687,50.
Ny adresse: Vandtårnsvej 62A, 1. b, 2860 Søborg
Vedtægter ændret: 01.12.2025
Kapitalforhøjelsen er besluttet den 01.12.2025.
kr. 300,00, indbetalt kontant, kurs 250.000,00.
Kapitalen udgør herefter kr. 183.500,00.
Vedtægter ændret: 10.11.2025
Kapitalforhøjelsen er besluttet den 10.11.2025.
kr. 300,00, indbetalt kontant, kurs 250.000,00.
Kapitalen udgør herefter kr. 183.200,00.
Ny adresse: Vandtårnsvej 62A, 1. e, 2860 Søborg
Ny kommune: Gladsaxe
Vedtægter ændret: 31.10.2025
Vedtægter ændret: 04.08.2025
Kapitalforhøjelsen er besluttet den 04.08.2025.
kr. 22.500,00, indbetalt kontant, kurs 75.000,00.
Kapitalen udgør herefter kr. 182.900,00.
Vedtægter ændret: 02.04.2025
Kapitalforhøjelsen er besluttet den 02.04.2025.
kr. 400,00, indbetalt kontant, kurs 250.000,00.
Kapitalen udgør herefter kr. 160.400,00.
Vedtægter ændret: 19.03.2025
Revision:
Fratrådte:
Beierholm Godkendt Revisionspartnerselskab, den 20.02.2025.
Tiltrådte:
CVR-NR. 33256876 CROWE STATSAUTORISERET REVISIONSINTERESSENTSKAB, Rygårds Allé 104, 2900 Hellerup, den 20.02.2025.
Ny adresse: Dyrehavevej 3, st., 2930 Klampenborg
Ny adresse: Dyrehavevej 2, st. 3, 2930 Klampenborg
Vedtægter ændret: 28.06.2024
Bestyrelse:
Fratrådte:
Kiri Lillan Glæsner, den 28.06.2024, Christian Torben Hill-Madsen, (formand), den 28.06.2024, Allan Traugott Wehnert, den 28.06.2024.
Direktion:
Fratrådte:
Tom Glæsner Larsen, den 28.06.2024.
Tiltrådte:
Christian Torben Hill-Madsen, den 28.06.2024, Allan Traugott Wehnert, den 28.06.2024.
Selskabet tegnes af direktionen i forening.
Vedtægter ændret: 06.02.2024
Første regnskabsår: 28.11.2023 - 30.04.2025
Nyt navn: NEUROINNOVATECH ApS
Bestyrelse:
Tiltrådte:
Kiri Lillan Glæsner, den 06.02.2024, Christian Torben Hill-Madsen, (formand), den 06.02.2024, Allan Traugott Wehnert, den 06.02.2024.
Selskabet tegnes af direktøren i forening med bestyrelsesformanden eller af den samlede bestyrelse.
Revision:
Tiltrådte:
CVR-NR. 32895468 BEIERHOLM, STATSAUTORISERET REVISIONSPARTNERSELSKAB, Knud Højgaards Vej 9, 2860 Søborg, den 06.02.2024.
Regnskabsår ændret til: 01.05 - 30.04
Vedtægter ændret: 09.01.2024
Kapitalforhøjelsen er besluttet den 09.01.2024.
kr. 120.000,00, indbetalt kontant, kurs 100,00.
Kapitalen udgør herefter kr. 160.000,00.
Stiftelsesdato: 28.11.2023.
Virkningsdato: 28.11.2023.
Seneste vedtægtsdato: 28.11.2023.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.000,00 til kurs 100,00, fuldt indbetalt.
Stifter:
CVR-NR. 43730967 Alteral Therapeutics ApS, Mesterlodden 3A, 1., 2820 Gentofte, den 28.11.2023.
Direktion:
Tom Glæsner Larsen, den 28.11.2023.
Selskabet tegnes af en direktør.
Første regnskabsår:
28.11.2023 - 31.12.2024.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at udvikle repositionerede lægemidler samt dermed beslægtet virksomhed.
P-number 1029901569Vandtårnsvej 62, 2860 Søborg